Donato Alarcón‐segovia

Donato Alarcón‐segovia's AcademicInfluence.com Rankings

Biology

#6163

World Rank

#8819

Historical Rank

Immunology

#315

World Rank

#327

Historical Rank

Molecular Biology

#615

World Rank

#630

Historical Rank

Genetics

#571

World Rank

#650

Historical Rank

biology Degrees

Download Badge

Biology

Donato Alarcón‐segovia's Degrees

PhD Genetics Stanford University

Why Is Donato Alarcón‐segovia Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Donato Alarcón‐segovia's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans (2002) (783)
Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients (1989) (632)
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus (1995) (561)
Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. (2000) (478)
Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. (2005) (406)
The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity Among “Hispanics” (2004) (398)
Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. (1982) (397)
Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. (1989) (378)
Vasculitis in systemic lupus erythematosus (1997) (317)
Primary antiphospholipid syndrome. (1989) (297)
Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. (1992) (272)
Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. (1995) (259)
Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors (1978) (249)
Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. (1992) (247)
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. (2003) (240)
Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. (1990) (185)
CLINICAL AND EXPERIMENTAL STUDIES ON THE HYDRALAZINE SYNDROME AND ITS RELATIONSHIP TO SYSTEMIC LUPUS ERYTHEMATOSUS (1967) (183)
Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. (2005) (173)
Features of Sjögren's syndrome in primary biliary cirrhosis. (1973) (162)
How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI). (1993) (159)
Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature. (1990) (157)
Box 1. Autoantibodies that penetrate cells (1996) (156)
Antiphospholipid arterial vasculopathy. (1989) (151)
Drug-induced lupus syndromes (1969) (142)
Epitope mapping and reactivity of autoantibodies to the E2 component of 2‐oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2‐oxoglutarate dehydrogenase complex (1996) (136)
Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. (1997) (134)
Systemic Lupus Erythematosus in Males A Study of 107 Latin American Patients (1996) (124)
Autoimmune thyroid disease in primary Sjögren's syndrome. (1995) (123)
Broken dogma: penetration of autoantibodies into living cells. (1996) (121)
Lymphopenia In Systemic Lupus Erythematosus (1978) (115)
A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31. (2002) (114)
Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. (1994) (113)
Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients (2005) (111)
Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome. (1995) (109)
Deforming arthropathy of the hands in systemic lupus erythematosus. (1988) (109)
The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. (1996) (105)
SYSTEMIC LUPUS ERYTHEMATOSUS FOLLOWING THYMECTOMY FOR MYASTHENIA GRAVIS: Report of Two Cases (1963) (100)
Antibody penetration into living cells. II. Anti-ribonucleoprotein IgG penetrates into Tgamma lymphocytes causing their deletion and the abrogation of suppressor function. (1979) (100)
Prophylaxis of the antiphospholipid syndrome: a consensus report (2003) (99)
Sjögren's syndrome in progressive systemic sclerosis (scleroderma). (1974) (98)
Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo (2003) (98)
Interleukin-1 and Interleukin-6 Activities are Increased in the Cerebrospinal Fluid of Patients with CNS Lupus Erythematosus and Correlate with Local Late T-Cell Activation Markers (1992) (95)
Sjögren's syndrome in systemic lupus erythematosus. Clinical and subclinical manifestations. (1974) (94)
Fatal pulmonary hemorrhage in systemic lupus erythematosus. Occurrence without hemoptysis. (1985) (92)
Long-term evaluation of colchicine in the treatment of scleroderma. (1979) (92)
Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies. (1988) (91)
Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. (1989) (90)
Remission of Systemic Lupus Erythematosus (1996) (88)
Systemic lupus erythematosus as a cause and prognostic factor of acute pancreatitis. (2004) (86)
The antiphospholipid/cofactor syndromes. (1996) (85)
Autoantibodies in systemic lupus erythematosus. (1998) (84)
Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. (1994) (84)
Prevalence of battering among 1780 outpatients at an internal medicine institution in Mexico. (2002) (78)
The necrotizing vasculitides. A new pathogenetic classification. (1977) (76)
Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels. (1997) (75)
Oral manifestations in patients with Sjögren's syndrome. (1998) (75)
Autologous rosette-forming T cells as the responding cells in human autologous mixed-lymphocyte reaction. (1980) (73)
The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage. (1996) (70)
T-cell dysregulation in patients with hyperprolactinemia: effect of bromocriptine treatment. (1986) (69)
Serum anti-β2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients (1999) (68)
Systemic lupus erythematosus presenting as panniculitis (lupus profundus). (1975) (67)
Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance. (1978) (67)
Hemocytopenia in systemic lupus erythematosus. Relationship to antiphospholipid antibodies. (1989) (67)
Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes. (1990) (67)
Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to reactivity of anticardiolipin antibody with thrombomodulin. (1989) (66)
A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus. (1997) (65)
Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. (1989) (62)
Human post-thymic precursor cells in health and disease. I. Characterization of the autologous rosette-forming T cells as post-thymic precursors. (1981) (61)
Natural anticoagulants in systemic lupus erythematosus. Deficiency of protein S bound to C4bp associates with recent history of venous thromboses, antiphospholipid antibodies, and the antiphospholipid syndrome. (1991) (60)
Articular manifestations of mixed connective tissue disease. (1979) (60)
Antibody penetration into living cells. I. Intranuclear immunoglobulin in peripheral blood mononuclear cells in mixed connective tissue disease and systemic lupus erythematosus. (1979) (59)
Fine mapping of the SLEB2 locus involved in susceptibility to systemic lupus erythematosus. (2000) (59)
Antibodies to histones in systemic lupus erythematosus. (1979) (59)
Decreased circulating thymus-derived cells with receptors for the Fc portion of immunoglobulin G in systemic lupus erythematosus. (1978) (58)
Pleuro-pulmonary manifestations of systemic lupus erythematosus. (1961) (58)
Mixed connective tissue disease and overlap syndromes. (1994) (57)
Pathogenetic potential of antiphospholipid antibodies. (1988) (57)
Involvement of the urinary bladder in systemic lupus erythematosus. A pathologic study. (1984) (56)
Both risk alleles for FcγRIIA and FcγRIIIA are susceptibility factors for SLE: a unifying hypothesis (2004) (56)
Antibody penetration into living cells: pathogenic, preventive and immuno-therapeutic implications. (2003) (54)
Hemolytic anemia and thrombocytopenic purpura: two related subsets of systemic lupus erythematosus. (1977) (54)
Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus. (1993) (54)
Factors associated with fetal losses in severe systemic lupus erythematosus (1996) (53)
Salmonella arizona arthritis and septicemia associated with rattlesnake ingestion by patients with connective tissue diseases. A dangerous complication of folk medicine. (1991) (53)
Antinuclear antibodies in patients on anticonvulsant therapy. (1972) (52)
Overlap syndromes in the context of shared autoimmunity (2005) (52)
Association between a T cell receptor restriction fragment length polymorphism and systemic lupus erythematosus. (1990) (52)
Effects of L-canavanine on T cells may explain the induction of systemic lupus erythematosus by alfalfa. (1985) (52)
Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment. (1971) (52)
Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE) (1997) (51)
Clinical manifestations of the antiphospholipid syndrome. (1992) (51)
Will some day PAPS fade into SLE? (1996) (51)
The role of HLA-DR alleles and complotypes through the ethnic barrier in systemic lupus erythematosus in Mexicans (1996) (50)
The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to beta 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. (1997) (49)
Articular manifestations of primary Sjögren's syndrome. (1983) (49)
Primary antiphospholipid syndrome as a cause of intestinal infarction. (1992) (48)
Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients. (1995) (48)
Autoantibodies in systemic lupus erythematosus. (1996) (48)
Defective monocyte production of, and T lymphocyte response to, interleukin-1 in the peripheral blood of patients with systemic lupus erythematosus. (1984) (47)
Oral candidiasis and Sjögren's syndrome. (1998) (47)
Erythermalgia, erythromelalgia, or both? Conditions neglected by rheumatologists. (1993) (46)
Valine/valine genotype at position 247 of the beta2-glycoprotein I gene in Mexican patients with primary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies. (2003) (46)
Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosus (2004) (45)
Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal. (1979) (45)
Antibody penetration into living cells. IV. Different effects of anti-native DNA and anti-ribonucleoprotein IgG on the cell cycle of activated T gamma cells. (1983) (45)
Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients with pss (1977) (44)
Quality of life in rheumatoid arthritis: validation of a Spanish version of the Arthritis Impact Measurement Scales (Spanish-AIMS) (1994) (44)
Genetic analysis of the contribution of IL10 to systemic lupus erythematosus. (1999) (43)
Systemic lupus erythematosus. Differences between patients who do, and who do not, fulfill classification criteria at the time of diagnosis. (1980) (43)
Abnormal esophageal motility in primary Sjögren's syndrome. (1976) (43)
Relationship between antiphospholipid antibodies and recurrent fetal loss in patients with systemic lupus erythematosus and apparently healthy women. (1989) (43)
Spontaneous production of, and defective response to, interleukin-1 by peripheral blood mononuclear cells from patients with scleroderma. (1985) (43)
Association of partial lipodystrophy and Sjögren's syndrome. (1976) (41)
Comparative Effectiveness of Packages of Treatment Including Ultrasound or Transcutaneous Electrical Nerve Stimulation in Painful Shoulder Syndrome (1993) (41)
T-cell subpopulations in the peripheral blood of patients with connective tissue diseases as determined by flow cytometry using monoclonal antibodies. (1983) (41)
Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial. (1984) (40)
Penetrating anti-DNA monoclonal antibodies induce activation of human peripheral blood mononuclear cells. (1998) (40)
Listeriosis in patients with connective tissue diseases. (1994) (40)
Hidden anti‐phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments (1998) (39)
Lupus erythematosus cell phenomenon in patients with chronic ulcerative colitis * (1965) (39)
From benign polyclonal to malignant monoclonal lymphoproliferation in a patient with primary Sjögren's syndrome. (1981) (39)
Sarcroilaic joints in primary gout. Clinical and roentgenographic study of 143 patients. (1973) (38)
Clinical, histopathological, immunological and fibroblast studies in 30 patients with subcutaneous injections of modelants including silicone and mineral oils. (1994) (37)
Diabetes insipidus secondary to Wegener's granulomatosis: report and review of the literature. (1991) (37)
Reference reagents for antinuclear antibodies (1988) (37)
Symptomatic Sjögren's syndrome in mixed connective tissue disease. (1976) (36)
Penetration of anti-DNA antibodies into immature live cells. (1998) (35)
Some patients with primary antiphospholipid syndrome have increased circulating CD5+ B cells that correlate with levels of IgM antiphospholipid antibodies. (1991) (35)
Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome (1996) (35)
Penetration of autoantibodies into living cells, 2000. (2001) (35)
Remission of systematic lupus erythematosus. (1996) (35)
Raynaud's phenomenon in primary Sjögren's syndrome. Association with other extraglandular manifestations. (1992) (34)
Immunoregulatory circuits in the acquired immune deficiency syndrome and related complex. Production of and response to interleukins 1 and 2, NK function and its enhancement by interleukin-2 and kinetics of the autologous mixed lymphocyte reaction. (1985) (34)
Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study (1995) (34)
Heterogeneity of the spontaneously expanded and mitogen-induced generation of suppressor cell function of T cells on B cells in systemic lupus erythematosus. (1980) (34)
Antibodies to nucleoprotein and to hydrazide-altered soluble nucleoprotein in tuberculous patients receiving isoniazid. (1969) (34)
Myositis in primary Sjögren's syndrome. Report of 3 cases. (1994) (34)
Phospholipid specificity and requirement of beta 2-glycoprotein-I for reactivity of antibodies from patients with primary antiphospholipid syndrome. (1992) (34)
Human postthymic precursor cells in health and disease. VII. Immunoregulatory circuits of the peripheral blood mononuclear cells from patients with progressive systemic sclerosis. (1981) (34)
Antiphospholipid antibodies. Where do they come from? Where do they go? (1994) (33)
Hyperprolactinemia inhibits natural killer (NK) cell functionin vivo and its bromocriptine treatment not only corrects it but makes it more efficient (1992) (33)
Immunochemical characterization of the anti-RNA antibodies found in scleroderma and systemic lupus erythematosus. I. Differences in reactivity with Poly (U) and Poly-(A) Poly (U). (1975) (33)
Salmonella pericarditis with tamponade in systemic lupus erythematosus. (1990) (33)
Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin (2004) (32)
The range and specificity of antinuclear antibodies in systemic lupus erythematosus. (1970) (32)
Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus (1991) (32)
The Concept and Classification of Antiphospholipid/Cofactor Syndromes (1996) (31)
Antigenic specificity of chlorpromazine-induced antinuclear antibodies. (1973) (31)
Class II allele and haplotype frequencies in Mexican systemic lupus erythematosus patients: the relevance of considering homologous chromosomes in determining susceptibility. (2001) (30)
Abnormalities in the content of nucleic acids of peripheral blood mononuclear cells from patients with systemic lupus erythematosus. (1982) (30)
Leg ulcers in the primary antiphospholipid syndrome. Report of a case with a peculiar proliferative small vessel vasculopathy. (1991) (30)
Association analysis with microsatellite and SNP markers does not support the involvement of BCL-2 in systemic lupus erythematosus in Mexican and Swedish patients and their families (2000) (30)
HLA class I and class II alleles and haplotypes in Mexican mestizos established from serological typing of 50 families. (1997) (30)
Cimetidine abrogates suppressor T cell function in vitro. (1981) (29)
Serum Hyperviscosity in Sjögren's Syndrome: Interaction Between Serum IgG and IgG Rheumatoid Factor (1974) (29)
Human post-thymic precursor cells in health and disease. VI. Effect of serum thymic factor on the response of cells from patients with systemic lupus erythematosus or mixed connective tissue disease in autologous mixed lymphocyte reaction. (1981) (29)
Erythermalgia. A clue to the early diagnosis of myeloproliferative disorders. (1966) (28)
Diversity and pattern of inheritance of autoantibodies in families with multiple cases of systemic lupus erythematosus. (1992) (28)
URACIL-SPECIFIC ANTI-R.N.A. ANTIBODIES IN SCLERODERMA (1975) (28)
Both risk alleles for FcgammaRIIA and FcgammaRIIIA are susceptibility factors for SLE: a unifying hypothesis. (2004) (28)
Probable depiction of juvenile arthritis by Sandro Botticelli. (1983) (28)
The pathogenesis of immune dysregulation in systemic lupus erythematosus. A troika. (1984) (28)
Natural killer cell activity in the systemic connective tissue diseases. (1988) (28)
Frequencies of HLA‐A and HLA‐B alleles in a Mexico City mestizo sample (1997) (27)
Decrease in serum antiphospholipid antibody levels upon development of nephrotic syndrome in patients with systemic lupus erythematosus: relationship to urinary loss of IgG and other factors. (1992) (27)
Suppressor cell loss and dysfunction in mixed connective tissue disease. (1980) (27)
Shared autoimmunity: A concept for which the time has come (2005) (27)
Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects. (2002) (27)
Retinal microangiopathy in systemic lupus erythematosus. (1975) (27)
A comparison of genome-scans performed in multicase families with systemic lupus erythematosus from different population groups. (1999) (26)
Antiphospholipid antibodies in patients with idiopathic autoimmune haemolytic anemia. (1994) (26)
Chronic interstitial cystitis as an initial major manifestation of systemic lupus erythematosus. (1981) (25)
Esophageal motility in systemic lupus erythematosus (1974) (25)
Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission (2003) (25)
Marked destructive changes occurring in osteoarthric finger joints after intra-articular injection of corticosteroids. (1966) (25)
One thousand private rheumatology patients in Mexico City. (1983) (25)
HLA-B alleles and complotypes in Mexican patients with seronegative spondyloarthropathies. (1994) (24)
Splenectomy has a limited role in the management of lupus with thrombocytopenia. (2002) (24)
Presence of serum antibodies to coagulation protein C in patients with systemic lupus erythematosus is not associated with antigenic or functional protein c deficiencies (1993) (24)
The G20210A Polymorphism in the 3' -Untranslated Region of the Prothrombin Gene in Mexican Mestizo Patients with Primary Antiphospholipid Syndrome (1999) (24)
Prevalence of 13 autoantibodies and of the 16/6 and related pathogenic idiotypes in 465 patients with systemic lupus erythematosus and their relationship with disease activity (1997) (24)
The mechanism of action of L-canavanine in inducing autoimmune phenomena. (1985) (24)
Primary juvenile Sjögren's syndrome. (1988) (24)
Course of antiphospholipid antibodies in patients with primary antiphospholipid syndrome before, during and after pregnancy treated with low dose aspirin. Relationship of antibody levels to outcome in 7 patients. (1992) (24)
Antibody penetration into living cells. III. Effect of antiribonucleoprotein IgG on the cell cycle of human peripheral blood mononuclear cells. (1982) (24)
HLA-DR6 (possibly DRB1*1301) is associated with susceptibility to Takayasu arteritis in Mexicans (2005) (23)
Mixed connective tissue disease - a decade of growing pains. (1981) (23)
Activation markers on peripheral blood T cells from patients with active or inactive systemic lupus erythematosus. Correlation with proliferative responses and production of IL-2. (1991) (23)
Presence of hepatitis-associated antigen in systemic lupus erythematosus. (1972) (23)
The different faces of shared autoimmunity. (2006) (23)
Anti-Cardiolipin, Anti-Cardiolipin Plus Bovine, or Human β2Glycoprotein-I and Anti-Human β2Glycoprotein-I Antibodies in a Healthy Infant Population (2002) (23)
Stimulating and differentiation factors for human B lymphocytes in systemic lupus erythematosus. (1986) (23)
Cold-reactive lymphocytotoxic antibodies in mixed connective tissue disease. (1977) (23)
Association of HLA-DR5 (DR11) with systemic sclerosis (scleroderma) in Mexican patients. (1995) (22)
Natural killer cell activity in dermatomyositis-polymyositis. (1987) (22)
Lupus hair (1974) (22)
Diagnostic value of thyroid antibodies. (1967) (22)
Bone remodeling and osteophyte formation after remission of rheumatoid arthritis. (1989) (22)
T‐Lymphocyte Subpopulation in Untreated SLE (1977) (21)
Immunochemical determination of DNA in immune complexes present in the circulation of patients with systemic lupus erythematosus. (1998) (21)
Detection and partial characterization of immune complexes in patients with rheumatoid arthritis plus Sjogren's syndrome and with Sjogren's syndrome alone. (1982) (21)
Functional and immunochemical heterogeneity of antiphospholipid antibodies: a classification. (1992) (21)
Massive pulmonary hemorrhage in mixed connective tissue diseases. (1989) (21)
Human postthymic precursor cells in health and disease. II. Their loss and dysfunction in systemic lupus erythematosus and their partial correction with serum thymic factor. (1981) (21)
Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. (1999) (21)
Salivary gland involvement in diseases associated with Sjögren's syndrome. 1. Radionuclide & roentgenorgraphic studies. (1974) (21)
Slow acetylation phenotype in systemic lupus erythematosus. (1979) (21)
Joint contractures and scleroderma-like skin changes in the hands of insulin-dependent juvenile diabetics. (1983) (20)
Defects of the retinal pigment epithelium in scleroderma. (1991) (20)
Mutilans-like arthropathy in mixed connective tissue disease. (1979) (20)
Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. (2000) (20)
Case report: erythermalgia in systemic lupus erythematosus. (1973) (19)
Fever in adult onset Still's disease. Response to methotrexate. (1991) (19)
Human Post‐thymic Precursor Cells in Health and Disease (1981) (19)
Anetoderma in systemic lupus erythematosus: relationship to antiphospholipid antibodies (2000) (19)
Shared autoimmunity: The time has come (2004) (18)
Tween 20 detaches cardiolipin from ELISA plates and makes anticardiolipin antibodies undetectable regardless of the presence of beta 2-glycoprotein-I. (1994) (18)
The contribution of resting heart rate and routine blood tests to the clinical assessment of disease activity in systemic lupus erythematosus. (1994) (18)
The frequency of complement receptor type 1 (CR1) gene polymorphisms in nine families with multiple cases of systemic lupus erythematosus. (1989) (18)
Cellular bases of the production of and response to interleukin-2 in man: role of autologous rosette-forming T-cell subsets defined with monoclonal antibodies. (1983) (17)
C-reactive protein in the differential diagnosis between infection and disease reactivation in SLE. (1981) (17)
Serum immunoglobulins in pulmonary tuberculosis. (1971) (17)
Australia antigen in systemic lupus. (1971) (17)
Familial aspects of mixed connective tissue disease (MCTD). I. Occurrence of systemic lupus erythematosus in another member in two families and aggregation of MCTD in another family. (1978) (17)
SYSTEMIC LUPUS ERYTHEMATOSUS WITH ERYTHERMALGIA. (1963) (17)
TREATMENT OF SCLERODERMA (1974) (17)
Role of IL-10 in the abnormalities of early cell activation events of lymphocytes from patients with systemic lupus erythematosus. (1998) (16)
RADIOISOTOPIC EVALUATION OF SALIVARY GLAND DYSFUNCTION IN SJÖGREN’S SYNDROME (1971) (16)
Serum immunoglobulins in systemic lupus erythematosus. (1972) (16)
Antinuclear antibodies: to penetrate or not to penetrate, that was the question. (2001) (16)
Frontiers of SLE: review of the 5th International Congress of Systemic Lupus Erythematosus, Cancun, Mexico, April 20-25, 1998. (1999) (16)
Effect of CD28 antibody on T cells from patients with systemic lupus erythematosus. (1994) (16)
The anti-phospholipid antibody syndrome: clinical and serological aspects. (2000) (16)
Serum antibodies to distinct epitopes of the tissue‐type plasminogen activator (t‐PA) in patients with systemic lupus erythematosus (1995) (16)
Linkage disequilibrium of HLA-DR3 and HLA-DR4 with HLA-B alleles in Mexican patients with rheumatoid arthritis. (1994) (15)
Low dose MTX and NSAID induced "mild" renal insufficiency and severe neutropenia. (1991) (15)
Mononuclear cell-fibroblast interactions in scleroderma. (1988) (15)
Protein S deficiency associated to anti-protein S antibodies in a patient with mixed connective-tissue disease and its reversal by danazol. (1993) (15)
Long-term treatment of symptomatic osteoarthritis with benoxaprofen. Double-blind comparison with aspirin and ibuprofen. (1980) (14)
[Antiphospholipid syndrome]. (2020) (14)
Factors associated with disease severity in Mexican patients with rheumatoid arthritis. (1994) (14)
Differences in immunoregulatory T cell circuits between diphenylhydantoin-related and spontaneously occurring systemic lupus erythematosus. (1981) (14)
Anti-neuronal antibodies in antiphospholipid syndrome with central nervous system involvement: the difference from systemic lupus erythematosus (1995) (14)
The new prognosis of systemic lupus erythematosus: treatment-free remission and decreased mortality and morbidity. (2000) (14)
A method for high yield isolation and purification of anti-native DNA antibodies present in lupus sera. (1980) (14)
The connective tissue diseases as disorders of immune regulation. (1985) (14)
Ulceration and perforation of the nasal septum in systemic lupus erythematosus. (1969) (13)
Antibody penetration into living cells. V. Interference between two fc gamma receptor-mediated functions: antibody penetration and antibody-dependent cellular cytotoxicity. (1981) (13)
The autologous mixed lymphocyte reaction is not primarily due to xenoantigenic stimulation. (1983) (13)
Association of Behçet's syndrome with HLA-B5 in the Mexican mestizo population. (1981) (13)
Antinuclear antibodies and propylthiouracil therapy. (1972) (13)
T lymphocyte subsets, suppressor and contrasuppressor cell functions, and production of interleukin-2 in the peripheral blood of rheumatic fever patients and their apparently healthy siblings. (1990) (13)
Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome. (1996) (13)
Antiprothrombin Antibodies in Patients With Systemic Lupus Erythematosus or With Primary Antiphospholipid Syndrome (2002) (13)
Chondritis of the ear in Wegener's granulomatosis. (1977) (12)
[Sjögren's syndrome associated with thymoma]. (1971) (12)
Immunoglobulin heavy chain constant-region gene polymorphism in systemic lupus erythematosus. (2010) (12)
Patterns of antinuclear antibodies and lupus-activating drugs. (1975) (12)
Immunochemical characterization of the anti-RNA antibodies found in scleroderma and systemic lupus erythematosus. II. Reactivity with hsa-coupled, uridine-containing, monophosphoric ribodinucleotides. (1975) (12)
Peripheral blood lymphocyte subsets and serum immunoglobulins in Sheehan's syndrome and in normal women during the menstrual cycle. (1993) (12)
Longitudinal study on the production of and cellular response to interleukin-2 in patients with systemic lupus erythematocus (2004) (12)
Lupus subsets: relationship to genetic and environmental factors. (1980) (12)
Mixed connective tissue disease. Appearance of antibodies to ribonucleoprotein following corticosteroid treatment. (1979) (12)
The heterogeneity of anti-DNA antibodies in systemic lupus erythematosus and other diseases. (1975) (12)
Descriptions of therapeutic arthrocenthesis and of synovial fluid in a Nahuatl text from prehispanic Mexico. (1980) (12)
LYMPHOCYTOTOXIC ANTIBODIES DURING PREGNANCY IN SYSTEMIC LUPUS ERYTHEMATOSUS (1979) (11)
Drug-Induced Antinuclear Antibodies and Lupus Syndromes (2012) (11)
Drug-induced lupus syndromes. (1970) (11)
Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy. (2002) (11)
Malabsorption in rheumatoid arthritis: an unusual complication caused by amyloidosis. (1967) (11)
Anti-cardiolipin, anti-cardiolipin plus bovine, or human beta(2)glycoprotein-I and anti-human beta(2)glycoprotein-I antibodies in a healthy infant population. (2002) (11)
Effect of pregnancy on functions of circulating T cells from patients with systemic lupus erythematosus: correction of T-cell suppression and autologous mixed-lymphocyte responses. (1983) (11)
Immunogenetics of mixed connective tissue disease in a Mexican Mestizo population. (1999) (11)
Pathology of the Antiphospholipid Syndrome (2002) (11)
Ankylosing spondylitis and rheumatoid arthritis in a patient with Paget's disease. Differential effects of indomethacin, D-penicillamine, or gold sodium thiomalate in the respective arthritides. (1985) (11)
Sjögren's syndrome in Behçet's disease. (1973) (11)
Demography of serum immunoglobulins: differences in IgG and IgM levels in two normal Mexican adult populations. (1970) (11)
Interferon production by lymphocytes from patients with systemic lupus erythematosus. (1974) (11)
Sjögrenʼs syndrome in systemic lupus erythematosus (1975) (10)
Antiphospholipid Antibodies and the Antiphospholipid Syndrome (1997) (10)
Immunologic studies in patients with Takayasu's arteritis. III. Immunoregulatory changes. (1989) (10)
Detection of anticardiolipin antibodies in heat-inactivated normal human sera is not influenced by beta 2-glycoprotein-I. (1993) (10)
Early proliferative response in the human autologous mixed lymphocyte reaction in scleroderma. (1984) (10)
Protein-caloric malnutrition and systemic lupus erythematosus. (1980) (10)
Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients of patients with PSS. (1977) (10)
Malignant neoplasms in autoimmune rheumatic diseases: examination of the risk of developing a malignancy among five different rheumatic diseases in one institution. (2000) (10)
Identification of four subpopulations of IgG anticardiolipin antibodies in patients with primary antiphospholipid syndrome on the basis of their requirement for beta 2-glycoprotein-I and their unmasking by heat. (1994) (10)
Immunoregulatory circuits and potential treatment of connective tissue diseases. (1996) (10)
Pha‐Induced Cellular Cytotoxicity (1979) (9)
Primary biliary cirrhosis. Prompt relief of pruritus with azathioprine treatment. (1970) (9)
Autoimmune Rheumatic Diseases and Cancer: Evidence of Causality? (2000) (9)
Distribution of class I and class III MHC antigens in the Tarasco Amerindians. (2002) (9)
Development of sicca symptoms in systemic lupus erythematosus patients with existing subclinical abnormalities of lacrimal and/or salivary glands. (1979) (9)
Drug-related lupus syndromes and their relationship to spontaneously occurring systemic lupus erythematosus. (1991) (9)
Autoantibodies that Penetrate into Living Cells (1996) (9)
Human post-thymic precursor cells in health and disease. IX. Immunoregulatory T cell circuits in peripheral blood of patients with rheumatoid arthritis. (1981) (9)
Carbamazepine for tabetic pain. (1968) (8)
Connective tissue disease features after thallium poisoning. (1989) (8)
Human post-thymic precursor cells in health and disease. V. Stimulatory effect of serum thymic factor on the cell cycle of autologous-rosette forming and T gamma-cells. (1982) (8)
Air esophagogram and intestinal pseudoocclusion in a patient with scleroderma. (1991) (8)
Effect of the new immunoregulator AS-101 on in vitro functions of mononuclear cells from patients with systemic lupus erythematosus. (1989) (8)
The antiphospholipid story. (2003) (8)
Bilateral renal vein thrombosis and nephrotic syndrome in a patient with the Marfan syndrome. (1968) (8)
Optimal conditions in [3H]-thymidine uptake studies to prevent radiation damage to cells. A scintimetric and cytofluorographic analysis. (1981) (8)
The predestination of autoantibodies (2001) (8)
3 – ETIOPATHOGENESIS OF SYSTEMIC LUPUS ERYTHEMATOSUS: Itineraries of Three Troikas (2004) (8)
T-lymphocyte subpopulation in untreated SLE. Variations with disease activity. (1977) (7)
The Mosaic of Systemic Lupus Erythematosus: Highlights of the Third International Conference on SLE 13-15 April 1992 (1992) (7)
Human postthymic precursor cells in health and disease. IV. Abnormalities in immunoregulatory T cell circuits in mixed connective tissue disease. (1981) (7)
Vasculitis and the antiphospholipid syndrome. (2000) (7)
Connective tissue disorders and the bowel. (1989) (7)
Electron microscopy of the lupus erythematosus cell. (1963) (7)
Antibody penetration into living cells. A new mechanism of immunologically mediated damage. (1979) (7)
Antiphospholipid antibodies and the antiphospholipid syndrome. Clinical relevance in neuropsychiatric systemic lupus erythematosus. (1997) (7)
Circulating colony-forming units of granulocytes and monocytes/macrophages in systemic lupus erythematosus. (1989) (7)
Presence of a 16/6 related human anti-DNA common idiotype (SA1) in the anticardiolipin antibodies of patients with primary antiphospholipid syndrome. (1991) (7)
Differences in the production of and/or the response to interleukin-2 by T lymphocytes from patients with the various connective tissue diseases (2004) (7)
Mixed connective tissue disease: Some statements (1982) (6)
Immunoregulatory defects in juvenile rheumatoid arthritis. Comparison between patients with the systemic or polyarticular forms. (1988) (6)
Differences in the kinetics of the autologous mixed lymphocyte reaction between the various connective tissue diseases (2004) (6)
The frequency of a common anti-DNA antibody idiotype (16/6) in different populations of patients with systemic lupus erythematosus. (1991) (6)
Receptor and non-receptor-bearing lymphocytes in untreated systemic lupus erythematosus. Variations with disease activity. (1977) (6)
Vasculitis in the connective tissue diseases (2000) (6)
Erythromelalgia without thrombocythemia. (1985) (6)
The recovery of self tolerance in SLE (2001) (6)
Repigmentation of vitiligo under penicillamine therapy for rheumatoid arthritis. (1982) (6)
Immune-Complex Disease in Typhoid Fever (1975) (5)
Mixed connective tissue disease: a disorder of immune regulation. (1983) (5)
Free serum ribonucleoprotein in mixed connective tissue disease and other connective tissue diseases. (1978) (5)
The treatment of systemic lupus erythematosus. (1994) (5)
Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosus. (2004) (5)
The genetics of autoimmunity: the familial tendency of systemic lupus erythematosus. (1989) (5)
Immune mechanisms in chronic pancreatic disease (1964) (5)
Receptors for the third component of complement in the human glomerulus. (1976) (5)
β2-Glycoprotein-I mRNA transcripts are expressed by hepatocytes but not by resting or activated human endothelial cells (1998) (5)
Antibody Penetration Into Living Cells (1979) (5)
Polyarteritis nodosa, Churg-Strauss syndrome, and other eosinophilic syndromes. (1990) (4)
Bromelain-Treated Erythrocyte Autoantibodies (1996) (4)
Natural killer cell-mediated activity in mixed connective tissue disease and its response to induction by interleukin-2 (1984) (4)
ANTIBODY PENETRATION INTO LIVING CELLS: MECHANISMS AND CONSEQUENCES (1980) (4)
Does the thymus play opposite roles in SLE and myasthenia gravis? (1978) (4)
Echocardiographic evaluation of patients with rheumatoid arthritis (1983) (4)
PHA-induced cellular cytotoxicity. Inhibition by a nonimmunoglobulin factor present in sera from patients with active systemic lupus erythematosus. (1979) (4)
Osteoarthritic knees in a Pre-Columbian ceramic figure. (1980) (4)
Normotensive Hyperreninemia in Systemic Lupus erythematosus (1978) (4)
Depression as expressed in pre-Columbian Mexican art. (1980) (4)
Painful Baker's cysts. Differential diagnosis by scintillation scanning with technetium Tc 99m. (1969) (4)
Frontiers in SLE: Review of the 5th International Congress of systemic Lupus Erythematosus. (1999) (4)
Parasitic rheumatism by Endolimax nana. Objections. (1985) (4)
AIRWAYS IN RHEUMATOID DISEASE (1978) (3)
Presence of an IL-3-producing suppressor T cell resistant to cyclosporin A in the peripheral blood of patients with systemic lupus erythematosus. (1988) (3)
The future of treatment for systemic lupus erythematosus. (2001) (3)
Cellular immunity and its regulation in SLE. (1982) (3)
[Acute immunologic hydralazine reaction. Clinical and serological changes after hydralazine administration to a patient with circulating antinuclear antibodies]. (1972) (3)
Pathogenesis of systemic lupus erythematosus. Possible participation of antiphospholipid antibodies. (1989) (3)
Deforming arthropathy of the hands in SLE and the growing pains of MCTD. (1991) (3)
Shared autoimmunity: The concept and introduction (2005) (3)
Immune complexes in autoimmune diseases. Differences in immune complexes detected by cellular receptors for complement and for Fc domains of IgG. (1980) (3)
Botticelli and arthritis. (1985) (3)
Normotensive hyperreninemia in systemic lupus erythematosus. An indicator of tubular dysfunction. (1978) (3)
Gross splenomegaly in SLE. (1978) (3)
International Symposium Art, History and Antiquity of Rheumatic Diseases (1986) (2)
Survival of Mexican patients with systemic lupus erythematosus. (2001) (2)
Beta2-glycoprotein-I mRNA transcripts are expressed by hepatocytes but not by resting or activated human endothelial cells. (1998) (2)
Diagnosis of splenic infarction by scintillation scanning with Hg203-bromomercurihydroxypropane (Hg203-BMHP). (1970) (2)
Isoniazid, antinuclear antibodies and SLE. (1973) (2)
Behçet's disease. Report of twelve patients in the Mexican population. (1981) (2)
Sjögren's syndrome in children. (1990) (2)
Determination by laser nephelometry of immunoglobulins produced by mononuclear cells in culture. (1980) (2)
Update: Treatment of systemic lupus erythematosus (2002) (2)
Letter to the editor: “Mexican aspirin”—a derogatory term (1990) (2)
Primary Sjögren's syndrome. Six characters in search of an author. (1989) (2)
Lymphocytotoxic antibodies in mexican patients with systemic lupus erythematosus and their families relationship of disease activity in the probands to antibody cytotoxicity in their relatives. (1981) (2)
The role of the laboratory in rheumatology. Antibodies to nuclear and other intracellular antigens in the connective tissue diseases. (1983) (2)
INFARCTION AND CIRCULATING ANTICOAGULANT (1967) (2)
Kidney transplantation is a safe therapeutic tool in systemic lupus erythematosus. (2000) (2)
The mosaic of SLE-II: highlights of the fourth international conference on systemic lupus erythematosus—March 1995 (1995) (1)
Progressive systemic sclerosis. (1978) (1)
Unfair generalizations about mexican medicine (1973) (1)
Transient seropositive arthritis after thermal injury. (1972) (1)
[Acquired immunodeficiency syndrome. Clinical data and immunologic studies on 9 patients examined in Mexico]. (1984) (1)
[Active chronic liver diseases. Classification and diagnostic criteria]. (1972) (1)
Flow cytometry and the rheumatic diseases. (1991) (1)
[Characterization of subpopulations of circulating lymphocytes in patients with various connective tissue diseases (author's transl)]. (1979) (1)
Unrelated patients with discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) share the major histocompatibility complex (MHC) markers. Report of two Mexican families (1995) (1)
Detecting H.A.A. in small quaniities. (1971) (1)
On the catastrophic adjective for the antiphospholipid syndrome. (1993) (1)
Letter: Treatment of scleroderma. (1974) (1)
Anti-beta 2-glycoprotein I antibody testing in patients with antiphospholipid syndrome. (1997) (1)
Reply to the letter of H.M. Cheng (1996) (1)
Aberrant expression of the PD-1 and RUNX genes in activated CD4+ T cells in patients with systemic lupus erythematosus (2004) (1)
Treatment needed to achieve remission of SLE. (1999) (1)
Clinical Associations of Antibodies to Phospholipids and/or Their Protein Cofactors (1999) (1)
Immune mechanisms in chronic pancreatic disease (2005) (1)
"Mexican Aspirin"--a derogatory term. (1990) (1)
Antigenicity of various gluten fractions (2005) (1)
Autoantibodies in systemic lupus erythematosus. (1997) (1)
Course and Prognosis of the Antiphospholipid Syndrome (2002) (1)
[Esophageal function in progressive systemic sclerosis (scleroderma) Manometric study of 50 patients in radiological and clinical correlation]. (1979) (1)
[Acute myocardial infarction in a young male with scleroderma (author's transl)]. (1979) (1)
Letter: Pre-Columbian representation of Heberden's nodes. (1976) (1)
[The National Academy of Medicine in the teaching and research activities of the nation]. (1983) (0)
[Immunologic studies in patients with the acquired immunodeficiency syndrome]. (1987) (0)
Symptomatic Sjögren's syndrome in mixed connective tissue disease. (1976) (0)
Antilymphocytic antibodies in mixed connective tissue disease. (1983) (0)
Immune mechanisms and the pathogenesis of rheumatic diseases (1983) (0)
[The future of medical investigation in Mexico]. (2004) (0)
[Application of the basic sciences to clinical practice]. (1973) (0)
Serum Hyperviscosity in Sjögren's Syndrome (2020) (0)
[Function of the Fc receptors]. (1980) (0)
[Antibodies. I. Introduction]. (1974) (0)
[The concept of clinical investigation]. (1986) (0)
Lymphocyte receptors and mitogen or antigen induced in vitro cell proliferation in subacute sclerosing panencephalitis. (1978) (0)
[Degradation products of fibrinogen in connective tissue disorders: probable relation to the presence of microangiopathies]. (1971) (0)
[Polarteritis nodosa limited to the skin]. (1967) (0)
Letter to the editor (2001) (0)
Systemic venular insufficiency. (1972) (0)
F.56. Clinical Associations of the -129 and -463 Myeloperoxidase Promoter Polymorphism in Mexican Patients with Systemic Lupus Erythematosus (2006) (0)
Retrocardiac mass: a clue to the tuberculous nature of monarthritis. (1980) (0)
[Pulmonary abscess in Sjögren's syndrome. An unusual clinical manifestation]. (1984) (0)
Assessment of healing phenomena in rheumatoid arthritis: comment on the article by Rau and Herborn. (1996) (0)
Immunoglobulin light-chain type in Sjögren's syndrome. (1983) (0)
A defect in immunoregulatory synovial fluid T cells in Behcet's syndrome (1989) (0)
Examination of the Risk of Developing a Malignancy Among Five Different Rheumatic Diseases in One Institution: Malignant Neoplasms in Autoimmune Rheumatic Diseases (2000) (0)
Analysis of the TNFR 2 polymorphism M196R in Swedish and Mexican patients with systemic lupus erythematosus and rheumatoid arthritis (2004) (0)
Lupus Diathesis (1965) (0)
Systemic lupus erythematosus and Klinefelter's syndrome. (1977) (0)
Tophaceous gout as the emblem of a mid 19th century itinerant salesman in Paris. (1985) (0)
Analysis of the hSLE1 locus on chromosome 2q37 in Mexican multicase families (2000) (0)
Descriptions oftherapeutic arthrocenthesis andof synovial fluid inaNahuatl textfromprehispanic (1980) (0)
Subject Index, Vol. 89, 1993 (1993) (0)
How long does it take to describe 25 SLE antigen= antibody systems? (1999) (0)
Late onset mixed connective tissue disease. (1986) (0)
CHAPTER 5 – Scleroderma (1985) (0)
Curriculum vitae of John P. Merrill (1978) (0)
Problems with Pain Trials (1993) (0)
[The crisis as a challenge to medicine in Mexico]. (1984) (0)
Transient seropositive arthritis following thermal injury. A new immune-complex syndrome? (1972) (0)
Erythermalgia Review of 51 Cases Distribution of Patients According to Age at Onset and Type of Erythermalgia (2005) (0)
Letter: Unfair generalizations about Mexican medicine. (1973) (0)
[Generalized lupus erythematosus with agranulocytosis and hemolytic anemia caused by drugs]. (1968) (0)
Upon Development of Nephrotic Syndrome in Patients With Systemic Lupus Erythematosus: Relationship to Urinary Loss of IgG and Other Factors (1992) (0)
Contents, Vol. Ill, 1996 (1996) (0)
Young immunologist's finger. (1989) (0)
[Thyroid acropachy. Report of a clinical case documented using gammagraphy]. (1986) (0)
[Rheumatoid arthritis and polymyositis. Development of dermatomyositis in a patient with prolonged rheumatoid arthritis]. (1967) (0)
Probable role of interleukin-1 in the pathogenesis of scleroderma. (1985) (0)
Interleukin-2 in autoimmunity: on records, hypotheses, theories, and facts. (1983) (0)
Subject Index, Vol. 111 1996 (1996) (0)
[Antibodies. I. Introduction]. (1974) (0)
A patient who developed dermatomyositis after suffering for 7 years from rheumatoid arthritis. (2002) (0)
[Thrombocytopenia and thyroid disease. Possible relation to anti-phospholipid antibodies]. (1988) (0)
[Excess of antibodies]. (1974) (0)
Letter: immune-complex disease in typhoid fever. (1975) (0)
[Articular manifestations of primary hyperthyroidism]. (1973) (0)
Serum hyperviscosity in Sjögren's syndrome interaction between IgG and IgG rheumatoid factor. (1974) (0)
[Manometric changes in the esophagus in patients with polymyositis]. (1982) (0)
antiphospholipid syndrome Autoantibodies against the fibrinolytic receptor, annexin 2, in (2013) (0)
DIABETIC RETINOPATHY AND RHEUMATOID ARTHRITIS (1967) (0)
Contents, Vol. 89, 1993 (1993) (0)
Interview with Donato Alarcon-Segovia. What will happen tomorrow in the treatment of lupus?. Interview by Jean-Charles Piette. (1995) (0)
Location of tophi at Cushing's striae. (1984) (0)
[Homage to Dr. Salvador Zubirán (1898-1998)]. (1998) (0)

This paper list is powered by the following services:

Donato Alarcón‐segovia's Academic­Influence.com Rankings

Donato Alarcón‐segovia's Degrees

Why Is Donato Alarcón‐segovia Influential?

Donato Alarcón‐segovia's Published Works

Published Works

Donato Alarcón‐segovia's AcademicInfluence.com Rankings